Several genes can fuse with ALK to create oncogenic fusion proteins. The most common fusion partner in NSCLC is EML4, resulting in the EML4-ALK fusion. Other fusion partners include NPM1 (nucleophosmin), TFG (TRK-fused gene), and KIF5B (kinesin family member 5B). The specific fusion partner can influence the biology of the tumor and its response to treatment.
